Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Al-Hassan NN, Behzadian A, Caldwell R, Ivanova VS, Syed V, Motamed K, Said NA.

Neoplasia. 2012 Apr;14(4):259-70.

2.

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. Epub 2007 Sep 22.

PMID:
17891393
3.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
5.

The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Jo M, Takimoto S, Montel V, Gonias SL.

Am J Pathol. 2009 Jul;175(1):190-200. doi: 10.2353/ajpath.2009.081053. Epub 2009 Jun 4.

6.
7.
8.

High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.

Lutz V, Reuning U, Krüger A, Luther T, von Steinburg SP, Graeff H, Schmitt M, Wilhelm OG, Magdolen V.

Biol Chem. 2001 May;382(5):789-98.

PMID:
11517932
9.

Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.

Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y.

Gynecol Oncol. 2009 Aug;114(2):265-72. doi: 10.1016/j.ygyno.2009.04.031. Epub 2009 May 17.

PMID:
19450871
10.

High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.

Borgfeldt C, Bendahl PO, Gustavsson B, Långström E, Fernö M, Willén R, Grenman S, Casslén B.

Int J Cancer. 2003 Nov 20;107(4):658-65.

11.

Normalization of the ovarian cancer microenvironment by SPARC.

Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K.

Mol Cancer Res. 2007 Oct;5(10):1015-30.

12.
13.

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, Dano K, Kuhn W, Jänicke F, et al.

J Clin Invest. 1993 Nov;92(5):2160-7.

14.

Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.

Connolly BM, Choi EY, Gårdsvoll H, Bey AL, Currie BM, Chavakis T, Liu S, Molinolo A, Ploug M, Leppla SH, Bugge TH.

Blood. 2010 Sep 2;116(9):1593-603. doi: 10.1182/blood-2010-03-276642. Epub 2010 May 13.

15.

Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells.

Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R, Gonias SL.

Cancer Res. 2010 Nov 1;70(21):8948-58. doi: 10.1158/0008-5472.CAN-10-1936. Epub 2010 Oct 12.

16.

Molecular mechanisms underlying postoperative peritoneal tumor dissemination may differ between a laparotomy and carbon dioxide pneumoperitoneum: a syngeneic mouse model with controlled respiratory support.

Matsuzaki S, Bourdel N, Darcha C, Déchelotte PJ, Bazin JE, Pouly JL, Mage G, Canis M.

Surg Endosc. 2009 Apr;23(4):705-14. doi: 10.1007/s00464-008-0041-7. Epub 2008 Jul 12.

PMID:
18622550
17.
18.

Lysophosphatidic Acid Stimulates Urokinase Receptor (uPAR/CD87) in Ovarian Epithelial Cancer Cells.

Lizalek J, McKenna T, Huegel K, Marsh S, Carolan A, Kobliska A, Heying E, Gardner N, Miller G, Kotecki A, Henningsen M, Lundt A, Farley J, Ellerbroek SM.

Anticancer Res. 2015 Oct;35(10):5263-70.

PMID:
26408685
19.

Supplemental Content

Support Center